Literature DB >> 2892451

Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine.

F M Gengo1, C Gabos.   

Abstract

Altered central nervous system function as indicated by drowsiness and impaired psychomotor performance is often a consequence of the use of traditional antihistamines. Demonstration that newer agents lack these CNS effects requires quantitative and objective measurements that are sensitive enough to assess the psychomotor capabilities required for such activities as driving an automobile. These capabilities include extended attention span, vigilance, visual tracking, rapid information processing, and reaction time. We have used several psychomotor function tests to conduct two investigations assessing the CNS effects of cetirizine. In the first study, 12 healthy, atopic subjects received single oral doses of hydroxyzine 25 mg, cetirizine 10 mg and 20 mg, and placebo in a double-blind, four-way crossover study. Skin-wheal response to intradermal histamine, psychomotor effects, and serum concentrations of each drug were measured for 36 hours after each dose. The CNS effects were measured using critical flash-fusion frequency tests and Stroop word testing. Perceived feelings of drowsiness were measured using a visual analogue scale (VAS). In the second study, 15 healthy subjects received single oral doses of diphenhydramine 50 mg, cetirizine 5 mg, 10 mg, and 20 mg, and placebo in a double-blind, five-way crossover study. Skin-wheal response to intradermal histamine, psychomotor effects, and serum concentrations of each drug were measured for 24 hours after each dose. The CNS effects were measured using digit-symbol substitution testing. "Trails-B" maze tracking, and an analyzer of driving performance that assessed reaction time and vigilance.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2892451

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  11 in total

Review 1.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial.

Authors:  Joris C Verster; A Marit de Weert; Saskia I R Bijtjes; Mounir Aarab; Armand W A A van Oosterwijck; Erik J E Eijken; Marinus N Verbaten; Edmund R Volkerts
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

Review 3.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Peripheral antihistamine and central sedative effects of single and continuous oral doses of cetirizine and hydroxyzine.

Authors:  S Levander; M Ståhle-Bäckdahl; O Hägermark
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Histamine H1 receptor antagonist cetirizine impairs working memory processing speed, but not episodic memory.

Authors:  P van Ruitenbeek; A Vermeeren; W J Riedel
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 6.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Selecting the optimal oral antihistamine for patients with allergic rhinitis.

Authors:  Jeffrey M Lehman; Michael S Blaiss
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 8.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 9.  Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria.

Authors:  D M Campoli-Richards; M M Buckley; A Fitton
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 10.  Safety of antihistamines in children.

Authors:  A P Ten Eick; J L Blumer; M D Reed
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.